Previous close | 4.3500 |
Open | 4.3800 |
Bid | 4.4800 x 100 |
Ask | 4.5200 x 100 |
Day's range | 4.3300 - 4.5800 |
52-week range | 4.2500 - 12.7500 |
Volume | |
Avg. volume | 221,501 |
Market cap | 161.884M |
Beta (5Y monthly) | 0.05 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.4200 |
Earnings date | 08 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 19.50 |
FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and
scPharmaceuticals Inc. ( NASDAQ:SCPH ) shareholders might be concerned after seeing the share price drop 23% in the...
scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2023 Earnings Call Transcript March 13, 2024 scPharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.35, expectations were $-0.48. SCPH isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to scPharmaceuticals Fourth Quarter and […]